|
NRG Oncology is pleased to report the scientific articles that appeared during the previous week as well as an abstract accepted for presentation at the 2025 European Society for Medical Oncology (ESMO). This publications report includes links, when available, to the article, PubMed abstract, or association abstract.
ACCEPTED ABSTRACTS
Gross N, Attwood K, Ashford B, Barker C, Chen Y, Nagarajan P, Rischin D, Schmitt N, Tam S, Wise-Draper TM, Ward MC, Wu XC, Yom SS. NRG-HN014 (C-PRE): A randomized phase 3 study of neoadjuvant immunotherapy with response-adapted treatment versus standard-of-care treatment for patients with resectable stage III-IV (M0) cutaneous squamous cell carcinoma (cSCC). ESMO (European Society for Medical Oncology). 10/17/2025. Poster Presentation.
PUBLISHED ARTICLES
Basik M, Cecchini RS, De Los Santos JF, Umphrey HR, Julian TB, Mamounas EP, White JR, Lucas PC, Balanoff CR, Tan AR, Weber JJ, Edmonson DA, Brown-Glaberman UA, Diego EJ, Teshome M, Matsen CB, Seaward SA, Wapnir IL, Wagner JL, Tjoe JA, Thompson AM, Wolmark N. Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial. JAMA Surg. 2025 Jul 1;160(7):723-731. doi: 10.1001/jamasurg.2025.1072. Erratum in: JAMA Surg. 2025 Jul 1;160(7):826. doi: 10.1001/jamasurg.2025.1980. PMID: 40332918; PMCID: PMC12060017. Read more.
Braunstein LZ, Mitchell MP, Bandos H, Sikov WM, Khan AJ, Chen PY, Ganz PA, Jagsi R, White JR, Cecchini RS, Kang H, Puhalla SL, Bolton KL, Connolly EP, Stringer-Reasor EM, Gergelis KR, Julian TB, Mamounas EP, Wolmark N. NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. Future Oncol. 2025 Jul;21(16):2017-2025. doi: 10.1080/14796694.2025.2511586. Epub 2025 Jun 26. PMID: 40574381; PMCID: PMC12218515. Read more.
Please note the following upcoming meetings and abstract submission deadlines
UPCOMING MEETINGS:
AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sep 18-21, 2025; Baltimore, MD
American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA
Canadian Association of Radiation Oncology (CARO); Sep 10-13, 2025; Calgary, AB
International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI
PA Breast Cancer Coalition (PBCC); Oct 15, 2025; Harrisburg, PA
Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL
Society for Immunotherapy of Cancer (SITC); Nov 5-9, 2025; National Harbor, MD
UPCOMING ABSTRACT SUBMISSION DEADLINES:
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 22-26, 2025; Boston, MA; Submission deadline Jul 21, 2025, 1:00 pm ET; LBA and Clinical Trials Sep 10, 2025, 1:00 pm ET
American Society of Clinical Oncology (ASCO) GI; Jan 8-10, 2026; San Francisco, CA; Due to publications committee Aug 26, 2025; Submission deadline Sep 9, 2025, 11:59 pm ET; LBA Oct 9, 2025, 12:00 pm ET
American Society of Colon and Rectal Surgeons (ASCRS); May 9-12, 2026; Tampa, FL; Due to publications committee Sep 30, 2025; Submission deadline Oct 14, 2025, 11:59 pm ET; LBA / Clinical Trials Jan 28, 2026
European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany; LBA Sep 9, 2025, 21:00 CET (placeholder required)
European Society of Gynaecological Oncology (ESGO); Feb 26-Mar 1, 2026; Copenhagen, Denmark; Due to publications committee Oct 17, 2025; Submission deadline Oct 31, 2025, 23:59 CET; LBA Jan 15, 2026
European Society for Radiotherapy and Oncology (ESTRO); May 15-19, 2026; Stockholm, Sweden; Due to publications committee Oct 29, 2025; Submission deadline Nov 12, 2025; LBA Apr 8, 2026
International Gynecologic Cancer Society (IGCS); Nov 5-7, 2025; Cape Town, South Africa; LBA Sep 29, 2025 (placeholder required)
San Antonio Breast Cancer Symposium (SABCS); Dec 9-12, 2025; San Antonio, TX; LBA Sep 30, 2025, 11:59 pm CT
Society for Neuro-Oncology (SNO); Nov 19-23, 2025; Honolulu, HI; LBA Sep 2, 2025, 5:00 pm ET
SSO - Advanced Cancer Therapies; Feb 14-16, 2026; Fort Lauderdale, FL; Due to publications committee Oct 6, 2025; Submission deadline Oct 20, 2025
Society of Urologic Oncology (SUO); Dec 2-5, 2025; Dallas, TX; Due to publications committee Jul 22, 2025; Submission deadline Aug 5, 2025; LBA Oct 1, 2025
|